Background:

Etodolac (Lodine) is a selective Cyclooxygenase-2 (COX-2)?inhibitor with an IC50 of 53.5 nM.? Etodolac, a non-steroidal anti-inflammatory drug (NSAID), has been reported to treat osteoarthritis and rheumatoid arthritis.

Etodolac was able to abolish the cell size decrease and block caspase-3/7 activity in TNFα-induced isolated rabbit articular chondrocytes [1]. However, studies have shown that etodolac at 24h could induce cell death in human malignant rhabdoid tumor cells (FRTK-1) in a dose-dependent manner. Additionally, etodolac has shown to increase caspase-8, -9 and -3 activity 3 at 24 or 48 h in FRTK-1 [2].

参考文献:
[1] Kumagai K1,?Kubo M,?Imai S,?Toyoda F,?Maeda T,?Okumura N,?Matsuura H,?Matsusue Y.The COX-2 selective blocker etodolac inhibits TNFα-induced apoptosis in isolated rabbit articular chondrocytes. Int J Mol Sci.?2013 Sep 30;14(10):19705-15.
[2] Hakozaki M1,?Hojo H,?Kikuchi S,?Abe M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1). Oncol Rep.?2007 Jan;17(1):169-73.